Physician profile
Timothy A Feger
NPI 1215937693
$9,948.99
in general payments reported to CMS, 2019-2025
30 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $655 · 2021: $1,266 · 2022: $2,177 · 2023: $1,675 · 2024: $1,756 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,909 · Consulting Fee: $28.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,909.25 |
| Consulting Fee | $28.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,737.08 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $1,561.05 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $1,258.52 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,226.03 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $697.99 | 2019-2025 | |
| Kaleo, INC. | $529.86 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $442.85 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Teva Pharmaceuticals USA, INC. | $373.73 | 2019-2023 | Airduo Digihaler |
| Pfizer INC. | $247.56 | 2019-2024 | |
| Genentech USA, INC. | $238.71 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $217.22 | 2019-2025 | |
| Amgen INC. | $186.67 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.07 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Pulmonx Corporation | $149.00 | 2022 | |
| Pharming Healthcare, INC. | $121.95 | 2021-2025 | Ruconest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $115.20 | 2022-2024 | Xembify |
| Alk-Abello, INC | $113.16 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Blueprint Medicines Corporation | $112.69 | 2022-2025 | Ayvakit |
| Biocryst US Sales Co., LLC | $95.44 | 2023-2025 | Orladeyo |
| Optinose US, INC. | $75.75 | 2019-2023 | |
| Octapharma USA, INC. | $59.90 | 2021-2024 | Panzyga |
| Leo Pharma INC. | $41.49 | 2022 | |
| Sanofi-Aventis U.S. LLC | $39.82 | 2019-2020 | |
| Mylan Specialty L.P. | $35.89 | 2022-2023 | Yupelri |
| Adma Biomanufacturing LLC | $28.29 | 2025 | |
| Shire North American Group INC | $21.93 | 2019 | |
| Hikma Pharmaceuticals USA | $21.29 | 2024 | Ryaltris |
| Bio Products Laboratory USA, INC. | $19.52 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $16.15 | 2025 | Neffy |
| Incyte Corporation | $13.18 | 2023 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Feger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.